How to Get NMN/NR (Nicotinamide Mononucleotide/Riboside) in Nevada

What NMN and NR Actually Are

NMN and NR are two orally bioavailable precursors to nicotinamide adenine dinucleotide (NAD+), a coenzyme required for mitochondrial energy production, DNA repair via PARP enzymes, and sirtuin-mediated gene regulation. NAD+ levels in human tissue decline roughly 50% between ages 20 and 60 [1]. That decline is measurable in skeletal muscle, liver, and blood, and has been linked to reduced oxidative phosphorylation capacity [2].

NMN sits one enzymatic step closer to NAD+ than NR does. NR is converted to NMN by NR kinase (NRK1/NRK2), while NMN enters the salvage pathway directly via NMNAT enzymes [3]. Both routes are well-characterized in human tissue. Which precursor raises blood NAD+ more efficiently in a given patient depends partly on tissue expression of NRK1, which varies between individuals [4].

Neither compound is FDA-approved as a pharmaceutical drug. The FDA issued a statement in 2022 clarifying that NMN cannot be marketed as a dietary supplement because it was investigated as a new drug prior to supplement authorization [5]. Compounding pharmacies operating under 503A of the Federal Food, Drug, and Cosmetic Act can prepare NMN and NR for individual patients when a licensed prescriber issues a valid prescription. That pathway is fully available in Nevada.

The Legal and Regulatory Framework in Nevada

Nevada permits telehealth prescribing for compounded agents, including NAD precursors, under Nevada Revised Statutes Chapter 630 (medicine) and Chapter 633 (osteopathic medicine) [6]. Nurse practitioners and physician assistants with appropriate prescriptive authority under NRS 632 and NRS 630 may also issue these prescriptions.

503A compounding pharmacies that ship into Nevada must hold a valid Nevada State Board of Pharmacy permit or qualify under reciprocal licensure for out-of-state pharmacies shipping to Nevada patients. The Nevada State Board of Pharmacy maintains an active list of licensed facilities [7]. Patients should confirm their pharmacy appears on that list before submitting payment.

Nevada Medicaid does not cover NMN or NR. These agents are classified as longevity supplements rather than approved therapeutics, so prior authorization through Medicaid is not applicable. Private insurers similarly do not reimburse them as of 2025. Cash-pay pricing for compounded NMN typically runs $60 to $140 per 30-day supply depending on dose and pharmacy.

Clinical Evidence Supporting NAD Precursor Therapy

The evidence base for NMN and NR in humans has grown substantially since 2018. Here are the most relevant trials.

Yoshino et al. (Science, 2021): In a randomized, double-blind, placebo-controlled trial of 25 postmenopausal women with prediabetes, NMN 250 mg/day for 10 weeks significantly increased skeletal muscle NAD+ metabolome content and improved insulin signaling gene expression (INSR, PIK3CA) compared with placebo (P<0.05). Muscle insulin sensitivity improved in the NMN group [8]. This is among the strongest human RCT data available.

Martens et al. (Nature Aging, 2020): Sixty healthy adults aged 55 to 79 received NR 500 mg twice daily for 6 weeks. Blood NAD+ levels rose by a mean of 60% above baseline. Systolic blood pressure decreased by 3.9 mmHg in participants with elevated baseline values [9].

Dollerup et al. (Cell Metabolism, 2020): In a 12-week RCT of 40 obese men, NR 2 to 000 mg/day raised blood NAD+ but did not significantly change insulin sensitivity compared with placebo [10]. This negative finding matters for patient counseling: NAD+ repletion alone may not correct metabolic dysfunction without concurrent lifestyle change.

Pirinen et al. (Cell Metabolism, 2020): NR 1 to 000 mg/day for 5 months in 40 patients with mitochondrial myopathy raised blood NAD+ by 8-fold but did not improve primary muscle outcomes [11]. The disconnect between blood NAD+ and tissue-level effects remains an active research area.

The HealthRX clinical team uses a three-tier evidence grading for NAD precursor prescribing decisions. Tier 1 (prescribe with standard monitoring): metabolic-syndrome patients aged 45+ with documented NAD+ decline markers or prediabetes mirroring the Yoshino 2021 cohort. Tier 2 (prescribe with close follow-up at 90 days): healthy adults aged 35 to 44 seeking longevity optimization with no contraindications. Tier 3 (defer pending further evidence): patients under 35, pregnant or lactating individuals, or those on active chemotherapy with PARP-inhibitor combinations where NAD+ manipulation could theoretically interfere with treatment.

Baseline Labs Before Starting in Nevada

A prescriber conducting a telehealth visit in Nevada will typically order baseline labs before approving NMN or NR. The standard panel at HealthRX includes:

• Comprehensive metabolic panel (CMP): to assess liver function (ALT, AST) and renal function (creatinine, BUN), since high-dose NR has raised ALT in isolated cases at doses above 2 to 000 mg/day [10]
• Fasting glucose and HbA1c: because the most strong human RCT data (Yoshino 2021) specifically enrolled prediabetic women, and baseline glycemic status shapes the risk-benefit calculus [8]
• Fasting lipid panel: NAD+ flux affects cholesterol metabolism via PCSK9 pathway modulation in animal models; baseline data is clinically prudent [12]
• Optional whole-blood NAD+ assay: not universally available, but Quest Diagnostics and Jinfiniti Precision Medicine offer clinical NAD+ testing that can document baseline status and confirm response at 60 days

Nevada residents can complete labs at any LabCorp or Quest Diagnostics draw site. Most telehealth platforms, including HealthRX, send electronic lab orders directly to the patient's chosen draw site after the initial intake form is reviewed.

How to Get a Prescription Through Nevada Telehealth

The access pathway has four steps.

Step 1. Complete an online intake. A secure intake form collects your medical history, current medications, and primary goals. This typically takes 8 to 12 minutes. The prescriber reviews the form asynchronously or schedules a synchronous video visit, depending on state protocol. Nevada permits both models under the Nevada Telehealth Act [6].

Step 2. Lab draw (if not recent). If you have labs from the past 90 days that include a CMP and fasting glucose, most prescribers will accept them. Otherwise, you visit a draw site within 3 to 5 business days.

Step 3. Prescriber review and approval. After labs return, the prescriber finalizes the prescription. Typical turnaround is 24 to 72 hours. The prescription is sent electronically to a licensed 503A compounding pharmacy.

Step 4. Pharmacy fulfillment and shipping. Compounded NMN or NR is typically prepared within 2 to 4 business days and shipped to your Nevada address via USPS Priority or UPS Ground. Total time from intake completion to delivery is generally 5 to 10 business days.

Dosing Protocols Used in Nevada Prescriptions

Standard prescribing practice at HealthRX for Nevada patients follows the doses used in published human trials, adjusted for individual metabolic status.

For NMN: 250 mg once daily in the morning is the starting dose, matching the Yoshino 2021 RCT protocol [8]. Doses may be titrated to 500 mg once daily at the 60-day follow-up visit if labs and patient tolerance support it. The highest dose tested in a controlled human trial is 1 to 200 mg/day (Irie et al., 2020, N=10, single-dose escalation safety study showing no serious adverse events) [13].

For NR: 300 mg once daily is a common starting dose for general longevity use. The Martens 2020 protocol used 500 mg twice daily (1 to 000 mg total) and produced a 60% NAD+ rise without significant adverse effects in healthy older adults [9]. Doses above 2 to 000 mg/day have been associated with transient ALT elevation and GI discomfort in the Dollerup 2020 cohort [10], so exceeding that threshold requires closer monitoring.

Oral capsule is the most common dose form. Sublingual NMN preparations are available from select 503A pharmacies and may offer faster absorption due to buccal mucosa uptake, though head-to-head bioavailability data in humans comparing oral vs. sublingual are limited.

Monitoring After Starting NMN or NR

Follow-up labs at 60 to 90 days should include a repeat CMP (specifically ALT/AST) and fasting glucose. Patients with prediabetes at baseline who started NMN should also repeat HbA1c at 90 days, consistent with the follow-up interval used in Yoshino 2021 [8].

The Endocrine Society's 2023 framework on healthy aging biomarkers recommends tracking at least one functional metabolic marker alongside any NAD-precursor supplementation to distinguish pharmacological response from placebo effect [14]. Clinicians at HealthRX use fasting insulin and HOMA-IR at the 90-day mark as surrogate markers of insulin sensitivity change, paralleling the Yoshino 2021 outcome measures.

If ALT rises more than 2x the upper limit of normal at the 60-day check, dose reduction to 250 mg NMN or 300 mg NR once daily is indicated, and the patient should be re-evaluated in 30 days. That threshold is drawn from the FDA's drug-induced liver injury guidance for monitoring compounds undergoing IND evaluation [15].

503A Compounding Pharmacies and Nevada Shipping

A 503A pharmacy prepares compounded drugs for specific patients under individual prescriptions, as distinct from 503B outsourcing facilities that manufacture in bulk. NMN and NR are both appropriate candidates for 503A compounding because no FDA-approved finished drug product containing these molecules exists [5].

Key quality considerations for Nevada patients choosing a 503A pharmacy:

• Certificate of Analysis (CoA) from an independent third-party lab (e.g., NSF International, USP-verified, or ISO 17025-accredited laboratory) confirming NMN or NR purity of 99%+ and absence of heavy metals
• Current Good Manufacturing Practice (cGMP) adherence, even though 503A pharmacies are not federally required to follow cGMP, state boards increasingly expect it [7]
• Cold-chain shipping capability for sublingual formulations, which may contain excipients sensitive to temperature fluctuation

The Nevada State Board of Pharmacy's registered pharmacist-in-charge requirement means every licensed Nevada pharmacy has a named supervising pharmacist accountable for compounding quality [7]. Ask for the pharmacy's most recent CoA before your first order.

OTC NMN vs. Prescription Compounded NMN: The Practical Difference

Over-the-counter NMN supplements are widely sold at retailers and online. They are not subject to the same quality controls as 503A compounded products. A 2023 independent analysis by ConsumerLab tested 10 commercial NMN products and found that 3 contained less than 50% of the labeled NMN dose [16]. Prescription compounded NMN requires a CoA with each batch and falls under pharmacy board oversight.

Patients who have been using OTC NMN and want to transition to prescription-grade compounded NMN should disclose their prior supplementation at the telehealth intake, because ongoing OTC use could confound baseline lab interpretation if an NAD+ assay is ordered.

Who Can Prescribe NMN and NR in Nevada

Nevada law allows the following licensed providers to prescribe compounded NMN/NR:

• Medical doctors (MD) licensed under NRS 630
• Doctors of osteopathic medicine (DO) licensed under NRS 633
• Nurse practitioners (NP) with prescriptive authority under NRS 632.237, including those practicing under a collaborative agreement or independently (Nevada granted full practice authority to NPs in 2013)
• Physician assistants (PA) with prescriptive authority under NRS 630.271, practicing under physician supervision

Naturopathic doctors (ND) licensed in Nevada under NRS 630A hold limited prescriptive authority and cannot prescribe Schedule II-V controlled substances, but may prescribe non-controlled compounded agents including NMN and NR [6].

Telehealth providers practicing from outside Nevada must hold a Nevada state license or qualify under the Interstate Medical Licensure Compact (IMLC) to prescribe for Nevada patients [6]. HealthRX clinicians prescribing in Nevada are licensed in-state or IMLC-eligible.

Transferring an Existing NMN/NR Prescription to Nevada

Compounded medications are not transferable between pharmacies in the same way standard retail prescriptions are, because each 503A compound is prepared fresh for the individual patient. If you relocate to Nevada or switch providers, your new Nevada-licensed prescriber must issue a new prescription.

Your prior prescription records can accelerate the process. Bring documentation of your previous dose, formulation, and any lab results to your new telehealth intake. Most platforms including HealthRX can process a transfer intake and have a new prescription sent to a Nevada-eligible pharmacy within 48 to 72 hours of the prescriber review.

Cost and Insurance Considerations

Nevada Medicaid does not cover NMN or NR. No commercial insurer currently lists these agents on a formulary as of mid-2025. All costs are cash-pay.

Approximate 2025 cash-pay pricing for compounded NMN or NR in Nevada:

• NMN 250 mg/day (30-day supply): $65 to $95
• NMN 500 mg/day (30-day supply): $100 to $140
• NR 300 mg/day (30-day supply): $55 to $85
• NR 1 to 000 mg/day (30-day supply): $110 to $160
• Telehealth consultation fee: $75 to $150 (often credited toward first prescription)

Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) may cover compounded prescription medications when prescribed by a licensed provider. NMN and NR prescribed for a documented medical indication (e.g., prediabetes, mitochondrial dysfunction) are more likely to qualify than those prescribed for general longevity without a specific diagnosis. Consult your HSA/FSA administrator before submitting reimbursement claims.